TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06343038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, 161Tb-SibuDAB,1GBq
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, 161Tb-SibuDAB,1GBq
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, 177Lu-PSMA-I&T, 1GBq
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, 177Lu-PSMA-I&T, 1GBq
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection, 161Tb-SibuDAB, Dose Escalation
Description: Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed.
Study: NCT05013658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pressure measurement
Description: pressure measurement with pilot balloon palpation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pressure measurement
Description: pressure measurement with pilot balloon palpation
Study: NCT05448404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
Study: NCT05003453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
Description: A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
Study: NCT04597307

Intervention type: COMBINATION_PRODUCT
Intervention: IN.PACT™ Admiral™ Drug Coated Balloon (DCB)
Description: For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
Study: NCT05942378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRXG-K-1939
Description: HRXG-K-1939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab is a programmed death-ligand 1 antibody
Study: NCT05358431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroimaging and electrophysiology
Description: Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
Study: NCT06115694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCI Articulating Introducer
Description: use

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: GlideRite® Rigid Stylet
Description: use
Study: NCT05210634

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil
Study: NCT06427070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irrigating solution
Description: Saline, sodium hypochlorite, chlorohexidine
Study: NCT06113224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection T0
Description: 2 blood samples will be taken in addition to the pre-operative check-up.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection T0
Description: 2 blood samples will be taken in addition to the pre-operative check-up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection 6 months
Description: 1 blood sample will be taken 6 months after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection 6 months
Description: 1 blood sample will be taken 6 months after surgery.
Study: NCT06422364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted Wearable Blanket provided by Dreamland Baby Co.
Description: All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
Study: NCT05554978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: patient receives landiolol in addition to standard-of-care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride (NaCl) 0.9%
Description: Placebo
Study: NCT06100094

Intervention type: OTHER
Intervention: semi-structured qualitative interviews
Description: During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file
Study: NCT05077462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1M Tab. and C52R2 Tab.
Description: Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1M Tab. and C52R2 Tab.
Description: Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52H
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52H
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
Study: NCT04090034

Intervention type: PROCEDURE
Intervention: Peptide Receptor Radionuclide Therapy
Description: a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
Study: NCT05162001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg
Description: Disulfiram used qd during nine weeks to observe effects on body weight
Study: NCT05059067

Intervention type: DEVICE
Intervention: Direct laryngoscopy for endotracheal intubation
Description: Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation

Intervention type: DEVICE
Intervention: Direct laryngoscopy for endotracheal intubation
Description: Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
Study: NCT05096260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based SMS/MMS and web content
Description: Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
Study: NCT06458608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: virtual reality glasses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: virtual reality glasses
Study: NCT05637203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)
Description: THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls.
Study: NCT06095427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY06006 (Denosumab Biosimilar)
Description: single dose of 60 mg LY006006 s.c.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Prolia (Denosumab)
Description: single dose of 60 mg US-Prolia s.c.
Study: NCT05637203

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discharge / Safety Planning
Description: * A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days
Study: NCT06303843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer with an electric ride-on car
Description: The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
Study: NCT06095427

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia
Description: single dose of 60 mg EU-Prolia s.c.
Study: NCT04598139

Intervention type: OTHER
Intervention: Study group
Description: The study group uses a web-based medication error notification system
Study: NCT04895085

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BinaxNOW Rapid Antigen System
Description: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Study: NCT04908930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-field activity group - Aim 3
Description: Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
Study: NCT05284266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction early
Description: Liposuction 6-9 months after inclusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction late
Description: Liposuction 18-21 months after inclusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard conservative treatment
Description: Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard conservative treatment with Intermittent Pneumatic Compression (IPC)
Description: Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
Study: NCT05607654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active iTBS
Description: Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study: NCT04860609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Bed Rest with lumbar Sacral Support~9. Home plan:~Exercises Posture Correction Precautions Contra indication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumber Spinal Decompression
Description: The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~9. Home plan:~Exercises Posture Correction Precautions Contra indication
Study: NCT06474208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Oral suspension of Vericiguat (BAY1021189) in single dose (SD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Oral suspension of Vericiguat (BAY1021189) in single dose (SD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Oral suspension of Vericiguat (BAY1021189) in single dose (SD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Oral suspension of Vericiguat (BAY1021189) in single dose (SD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Oral suspension of Vericiguat (BAY1021189) in single dose (SD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
Study: NCT04252950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB-SET
Description: Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization
Description: Endovascular revascularization is a primary treatment option for patients with PAD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: Endovascular revascularization is a primary treatment option for patients with PAD
Study: NCT06474208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
Study: NCT06552351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-Free Jet Injection of 1 % lidocaine
Description: The needle-free jet injection device delivers 1% lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.
Study: NCT04415788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test of Incremental Respiratory Endurance - IMT
Description: The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold - IMT
Description: The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IMT (Low resistence)
Description: The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
Study: NCT06474208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 4
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
Study: NCT04812054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion
Description: Hypothermic oxygenated perfusion using a Liver Assist device (Organ Assist, Groningen, the Netherlands). Temperature of the perfusate will be set to 12 degrees Celsius. Dedicated cannulas will be placed in the aorta for arterial perfusion and in the portal vein for portal perfusion. Pressure will be set at 25 mmHg for arterial line (pulsatile flow, 30 mmHg systolic pressure and 20 mmHg diastolic pressure, 60 beats per minute) and 3 mmHg for portal line (continuous flow). 100% oxygen will be supplied to the oxygenators with a flow of 500 ml / min or higher, in order to achieve pO2 of at least 450 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple cold storage
Description: Following back-table preparation, the allograft will either be transferred to the operating room for implantation or stored in preservation solution at 4 degrees Celsius in a refrigerator
Study: NCT05124951

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-ventricle irradiation
Description: Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
Study: NCT06552351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional needle infiltration of 1% lidocaine
Description: Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.
Study: NCT06074744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSNB + IPACK
Description: already included in arm/group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FNB + IPACK
Description: already included in arm/group description
Study: NCT05277454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-653
Description: Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment.
Study: NCT05100823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal cells sampling
Description: Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
Study: NCT05124951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/etoposide
Description: Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide/cisplatin/etoposide
Description: Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second-look surgery
Description: Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
Study: NCT05569187

Intervention type: DRUG
Intervention: Ribociclib
Description: Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
Study: NCT06474208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 4
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
Study: NCT05100823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal biopsy sampling
Description: Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.